Adenovirus News and Research

RSS

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.

Speed of vaccination is key to reducing COVID-19 spread, says study

Mathematical modeling of the effects of vaccine efficacy and the speed of vaccination show that a lower efficacy vaccine may curb disease transmission similar to that of a higher efficacy vaccine if the speed of immunization is high.

15 Apr 2021

Researchers work to develop dual antigen COVID-19 vaccine candidate

A new study has been published on the medRxiv* preprint server, which focuses on the development of a dual-antigen COVID-19' T cell' vaccine. This vaccine is developed based on the expression of both S protein and nucleocapsid (N) protein of SARS-CoV-2, using a next-generation human adenovirus serotype 5 (Ad5) platform.

12 Apr 2021

Oxford-AstraZeneca COVID vaccine induces cell spikes similar to SARS-CoV-2's

Scientists from the University of Oxford and the University of Southampton report in the journal ACS Central Science that cells infected with the ChAdOx1 vaccine produce spike proteins on the cells similar to those produced by natural SARS-CoV-2 infection.

9 Apr 2021

Can limiting the priming dose of a SARS-CoV-2 vaccine improve immunity?

Researchers from Northwestern University and the University of Rochester in the U.S. addressed this question in their study. The researchers also explored whether the vaccines administered across the world could confer sterilizing immunity while preventing severe disease and death.

6 Apr 2021

South Africa SARS-CoV-2 variant B.1.351 easily escapes Sputnik vaccine

A new preprint research paper posted to the medRxiv* server reports on vaccine resistance data that pushes the end of the pandemic further away.

6 Apr 2021

Researchers develop a recombinant SARS-CoV-2 receptor-binding domain trimer vaccine candidate

New research deals with the development of RBD trimer as a potent target for SARS-CoV-2 subunit vaccines. This study revealed the development of a trimeric RBD subunit vaccine candidate that could induce strong humoral and cellular immune responses in nonhuman primates (NHPs), namely, rhesus macaques.

1 Apr 2021

Antibodies produced from infection with SARS-CoV-2 501Y.V2 protect against other variants

A recent paper in the journal Nature shows that while earlier lineages do not elicit antibodies capable of efficiently neutralizing the newly emerged South African variant, SARS-CoV-2 501Y.V2 (B.1.351), the converse does occur.

31 Mar 2021

New portable viral screening test can diagnose COVID-19 in minutes and track variants

Clinicians using a new viral screening test can not only diagnose COVID-19 in a matter of minutes with a portable, pocket-sized machine, but can also simultaneously test for other viruses--like influenza--that might be mistaken for the coronavirus.

31 Mar 2021

Single Sputnik V vaccine dose elicits robust immune response in previously infected individuals

A new preprint research paper posted to the medRxiv server describes successful immunization of the vaccinated population with a single dose of the Russian-made Sputnik V vaccine.

29 Mar 2021

Dual-antigen COVID-19 vaccine elicits humoral and cellular immune responses in mice

The scientific consensus is that safe and highly effective vaccines are required to end the ongoing pandemic of coronavirus disease 2019 COVID-19, caused by SARS-CoV-2. A new study describes a new vaccine that presents two viral antigens to the human immune system, in order to elicit a more efficacious response.

25 Mar 2021

AstraZeneca's COVID-19 vaccine protects against symptomatic disease

Results from a large clinical trial in the United States and South America indicate that AstraZeneca's COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization.

22 Mar 2021

GMP-Ready Helper Plasmids for AAV Production

Manufactured in dedicated clean-rooms with mandated changeovers before new production cycles - AMSBIO introduces new pHelper-Kan plasmid DNA optimized for Adeno-Associated Virus (AAV) manufacturing.

18 Mar 2021

Antibodies to SARS-CoV-2 spike protein and RBD detected in saliva of mRNA-vaccine recipients

A team of researchers from the US and the Netherlands recently reported that antibodies to the spike protein and the RBD are detected in saliva samples from healthcare workers vaccinated with mRNA vaccines.

12 Mar 2021

Is a single mRNA COVID-19 vaccine dose enough for recovered individuals?

A new study deals with the evaluation of adaptive immune response to COVID-19 vaccination in candidates who have recovered from SARS-CoV-2 infection.

11 Mar 2021

New academic spin-out based in Finland introduces a nasal spray vaccine against COVID

Rokote Laboratories Finland Ltd., a newly-founded academic spin-out based in Finland is working to develop and introduce to the markets a nasal spray vaccine against COVID.

8 Mar 2021

UK public health authorities review early data on the effectiveness of Pfizer and AstraZeneca COVID-19 vaccines

A team of UK scientists has recently evaluated the effectiveness of the Pfizer (BNT162b2) and AstraZeneca (ChAdOx1) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The findings reveal that both vaccines are effective in significantly reducing SARS-CoV-2 infection in older adults and providing long-term protection.

3 Mar 2021

Delayed second dose strategy with mRNA vaccines may reduce COVID-19 mortality, say researchers

An interesting new preprint shows that even if countries are forced to delay the second dose of the current vaccines administered against SARS-CoV-2, to arrest the ongoing COVID-19 pandemic, the cumulative mortality would still fall significantly.

3 Mar 2021

SARS-CoV-2 viremia predicts severe COVID-19 disease outcomes

The SARS-CoV-2 plasma viremia has been linked to severe disease and death in COVID-19 cases in small-scale cohort studies. The current study, published on the pre-print server medRxiv, aimed to study the mechanisms behind this relationship.

2 Mar 2021

FDA issues EUA for third COVID-19 vaccine

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

1 Mar 2021

Why Astrazeneca and J&J’s vaccines, in use the world over, are still on hold in America

The World Health Organization greenlighted emergency use of AstraZeneca and Oxford's covid-19 vaccine this month, following in the steps of the United Kingdom, the European Union and others, who are already injecting it as quickly as possible into the masses.

26 Feb 2021